Processa Pharmaceuticals, Inc. (PCSA)
NASDAQ: PCSA · Real-Time Price · USD
0.860
-0.020 (-2.26%)
At close: Nov 22, 2024, 4:00 PM
0.870
+0.010 (1.16%)
After-hours: Nov 22, 2024, 7:57 PM EST

Company Description

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment.

Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.

The company’s pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.

It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica.

The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.

Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals logo
Country United States
Founded 2011
Industry Biotechnology
Sector Healthcare
Employees 13
CEO George Ng

Contact Details

Address:
7380 Coca Cola Drive, Suite 106
Hanover, Maryland 21076
United States
Phone 443 776 3133
Website processapharmaceuticals.com

Stock Details

Ticker Symbol PCSA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001533743
CUSIP Number 74275C205
ISIN Number US74275C3043
Employer ID 45-1539785
SIC Code 2834

Key Executives

Name Position
George K. Ng Esq., J.D. Chief Executive Officer and Director
Dr. David Young Ph.D., Pharm.D. Co-Founder, President of Research and Development and Director
Dr. Sian E. Bigora Ph.D., Pharm.D. Co-Founder and Chief Development and Regulatory Officer
Patrick Lin Co-Founder, Chief Business and Strategy Officer
Wendy J. Guy Co-Founder, Chief Administrative Officer and Corporate Secretary
Russell L. Skibsted M.B.A. Chief Financial Officer
Dr. Steven Cha M.D. Senior Vice President of Clinical Research

Latest SEC Filings

Date Type Title
Nov 6, 2024 8-K Current Report
Oct 30, 2024 10-Q Quarterly Report
Oct 2, 2024 8-K Current Report
Aug 28, 2024 8-K Current Report
Aug 13, 2024 10-Q Quarterly Report
Jul 30, 2024 8-K Current Report
Jul 22, 2024 S-8 Securities to be offered to employees in employee benefit plans
Jul 17, 2024 8-K Current Report
Jul 2, 2024 8-K Current Report
Jun 11, 2024 DEFR14A Filing